Abstract
Antibody distinct from that involved in neutralization and directed to an antigen (AG-4) induced in HEp-2 cells by infection with herpesvirus type 2 was identified in serums from patients with cervical carcinoma by means of a quantitative micro complement fixation test. The presence of antibody to AG-4 correlates well with the extent of the tumor; antibody is virtually absent in matched control women and in women with therapy and without recurrent neoplasia. Reactivity is not observed with control antigen consisting of a cell extract prepared from uninfected HEp-2 cells. The possible prognostic significance of this antibody and its implications are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
